Home > Financial Ratios > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Core EBITDA Growth

    Back to All Ratios
AD     Remove this Ad

GLENMARK PHARMACEUTICALS Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) 21.125.79-22.6416.5114.91

What is the latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS ?

The latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS is 21.12 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar202521.12
Mar20245.79
Mar2023-22.64
Mar202216.51
Mar202114.91

How is Core EBITDA Growth of GLENMARK PHARMACEUTICALS Trending?

Years Core EBITDA Growth % Change
Mar2025 21.12
264.77
Mar2024 5.79
Positive
Mar2023 -22.64
Negative
Mar2022 16.51
10.73
Mar2021 14.91 -

Other Financial Ratios of GLENMARK PHARMACEUTICALS


Compare Core EBITDA Growth ratio of peers of GLENMARK PHARMACEUTICALS

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS ₹55,740.1 Cr 1% -5% 36.9% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹408,991.0 Cr 0.1% -3.2% -2.6% Stock Analytics
DIVIS LABORATORIES ₹162,371.0 Cr -1.5% -7.3% 2.3% Stock Analytics
TORRENT PHARMACEUTICALS ₹135,229.0 Cr -1.3% -0.7% 24.4% Stock Analytics
CIPLA ₹108,441.0 Cr 1.5% -8.1% -6.3% Stock Analytics
DR REDDYS LABORATORIES ₹106,407.0 Cr 3.2% 5.6% 3.1% Stock Analytics


GLENMARK PHARMACEUTICALS Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS

1%

-5%

36.9%

SENSEX

2.9%

-1.1%

8.5%


You may also like the below Video Courses